人工智能与数字病理在成人中枢神经系统肿瘤中的机遇与挑战
本文综述了人工智能与数字病理在成人中枢神经系统肿瘤中的应用。2021年WHO第五版分类引入分层整合诊断,分子特征优先于组织学。AI可提升诊断一致性、缩短周转时间并整合多模态信息,但临床落地面临泛化性、透明度、隐私和监管等障碍。
要点
- 2021年WHO第五版CNS肿瘤分类确立分层整合诊断,分子特征与组织学冲突时以分子为准。
- AI与数字病理有望提升诊断一致性、缩短周转时间并整合组织学、分子和影像信息。
- 临床转化障碍包括泛化性有限、透明度不足、数据隐私和监管演变。
核心结论
- AI与数字病理正在改变成人CNS肿瘤诊断,可能提升精准性、效率和多学科决策。
- 成功实施需要严格的多机构临床验证、透明治理、公平可及和多方协作。
研究设计与样本
- 叙述性综述,检索PubMed中2021年WHO分类前后相关文献,覆盖数字病理、全切片成像和AI在成人神经肿瘤中的应用。
- 综合证据涉及诊断性能、分子预测、预后建模、工作流整合和伦理考量。
主要发现
- AI与数字病理有潜力提高诊断一致性、缩短周转时间并整合组织病理、分子和影像信息。
- AI模型可能支持胶质瘤分级、从常规组织学预测分子改变、生存分层、脑转移预测和术中决策。
临床怎么用
- 在神经肿瘤多学科诊疗中,可将AI辅助诊断与数字病理作为整合诊断的补充工具。
- 临床采纳前应关注模型泛化性、透明度、数据隐私和监管要求。
局限性
- 临床采纳障碍包括泛化性有限、缺乏透明度、数据隐私和监管演变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For over a century, the pathologist's interpretation at the microscope was the final word on a brain tumor's identity. The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors, 5th edition, changed that hierarchy by introducing a layered, integrated diagnosis in which molecular findings take precedence over histology when the two conflict. Artificial intelligence (AI) applied to digitized slides adds a computational layer to this framework and marks a fundamental change in diagnostic workflow. This review examines the role of AI and digital pathology in adult CNS tumors and discusses the opportunities and challenges in clinical, neuro-oncology implementation. METHODS: We conducted a narrative review of relevant literature indexed in PubMed before and after the 2021 WHO classification, covering digital pathology, whole-slide imaging (WSI), and AI applications in adult neuro-oncology. We synthesized evidence on diagnostic performance, molecular prediction, prognostic modeling, workflow integration, and ethical considerations. RESULTS: AI and digital pathology show potential to improve diagnostic consistency, shorten turnaround time, and integrate histopathological, molecular, and radiological information. AI models may support glioma grading, prediction of molecular alterations from routine histology, survival stratification, prediction of brain metastasis, and intraoperative decisions. Barriers to clinical adoption include limited generalizability, lack of transparency, data privacy, and evolving regulatory oversight. CONCLUSION: AI and digital pathology are transforming adult CNS tumor diagnostics and could improve precision, efficiency, and multidisciplinary decision-making. Successful implementation will require rigorous multi-institutional clinical validation, transparent governance, equitable access, and collaboration among patients and health care professionals.
引用
- Lechpammer M, Norrell JT, Parnas JN, et al. Opportunities and challenges of artificial intelligence and digital pathology in adult CNS tumors. J Neurooncol. 2026. PMID: 42902096. doi:10.1007/s11060-026-05833-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。